MX352824B - Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. - Google Patents

Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.

Info

Publication number
MX352824B
MX352824B MX2015009169A MX2015009169A MX352824B MX 352824 B MX352824 B MX 352824B MX 2015009169 A MX2015009169 A MX 2015009169A MX 2015009169 A MX2015009169 A MX 2015009169A MX 352824 B MX352824 B MX 352824B
Authority
MX
Mexico
Prior art keywords
levocetirizine
montelukast
formulations
methods
common cold
Prior art date
Application number
MX2015009169A
Other languages
English (en)
Inventor
Bruce Chandler May
Original Assignee
Inflammatory Response Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflammatory Response Res Inc filed Critical Inflammatory Response Res Inc
Publication of MX352824B publication Critical patent/MX352824B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las modalidades descritas en la presente incluyen métodos y formulaciones para el tratamiento de influenza, resfriado común, e inflamación aguda asociada. Los métodos y formulaciones incluyen pero no están limitados a métodos y formulaciones para administrar concentraciones efectivas de levocetirizina y montelukast a un paciente en necesidad del mismo. Los métodos y formulaciones pueden comprender elementos de liberación convencional y/o elementos de liberación modificada, proporcionando la administración del fármaco al paciente.
MX2015009169A 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. MX352824B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35552010P 2010-06-16 2010-06-16
PCT/US2011/040562 WO2011159821A1 (en) 2010-06-16 2011-06-15 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation

Publications (1)

Publication Number Publication Date
MX352824B true MX352824B (es) 2017-12-11

Family

ID=45348536

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009169A MX352824B (es) 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX2012014521A MX2012014521A (es) 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012014521A MX2012014521A (es) 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.

Country Status (10)

Country Link
US (5) US9044479B2 (es)
EP (2) EP2799071B1 (es)
JP (2) JP5781606B2 (es)
KR (2) KR20130050952A (es)
CN (2) CN107308161A (es)
AU (1) AU2011268342B2 (es)
CA (1) CA2802853C (es)
ES (1) ES2705244T3 (es)
MX (2) MX352824B (es)
WO (1) WO2011159821A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044479B2 (en) * 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
AU2014249530B2 (en) * 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
ES2745041T3 (es) * 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
AU2014249531B2 (en) * 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2017210417A1 (en) * 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions
WO2019004776A2 (en) * 2017-06-30 2019-01-03 Hanmi Pharm. Co., Ltd. COMPRESSED COMPOSITE CHEMICAL COMPRISING LEOVETITIZINE AND MONTELUKAST WITH IMPROVED STABILITY AND MEDICATION OBSERVANCE, AND PROCESS FOR PREPARING THE SAME
CN110312513B (zh) * 2017-07-05 2022-07-08 艾缇亚(上海)制药有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
US11844792B2 (en) 2020-07-10 2023-12-19 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
KR102481517B1 (ko) * 2021-08-30 2022-12-27 주식회사 클라시아 약제학적 제제
TR2021018192A1 (tr) * 2021-11-22 2023-06-21 Univ Istanbul Medipol Anti̇-vi̇ral etki̇ gösterebi̇lecek yeni̇ i̇laç formülasyonlarinin hazirlanmasi ve covi̇d-19?a karşi etki̇si̇ni̇n araştirilmasi
US20230190734A1 (en) * 2021-12-16 2023-06-22 IRR, Inc. Levocetirizine and montelukast in the treatment of coronavirus disease and symptoms thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP0808636A1 (en) 1991-11-14 1997-11-26 Alliance Pharmaceutical Corporation Method for partial liquid ventilation using fluorocarbons
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
HUP0001960A2 (hu) 1997-01-24 2000-10-28 Autoimmune, Inc. Metotrexát kombináció autoimmun tünetek befolyásolására
PL193131B1 (pl) 1997-12-23 2007-01-31 Schering Corp Kompozycja farmaceutyczna zawierająca kombinację składników aktywnych i jej zastosowanie
WO1999037155A1 (en) 1998-01-27 1999-07-29 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
MXPA03000848A (es) * 2000-07-28 2004-12-13 Immupharm Aps Metodos para el tratamiento de sintomas del resfriado comun, rinitis alergica e infecciones relacionadas con el tracto respiratorio.
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
RO122476B1 (ro) 2001-06-28 2009-07-30 Ucb S.A. Tabletă conţinând cetirizină şi pseudoefedrină
DE60227709D1 (de) 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
DE50312523D1 (de) 2002-05-24 2010-04-29 Carl-Fr Coester Pharmazeutische wirkstoffkombination sowie deren verwendung
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CA2518409A1 (en) 2003-03-12 2004-09-23 John P. Mullally Composition and method for treating inflammations by reducing c-reactive protein
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
FR2881823B1 (fr) 2005-02-08 2007-03-16 Siemens Vdo Automotive Sas Utilisation de la magneto-impedance sur un capteur de position sans contact et capteur correspondant
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
DE602006008665D1 (de) 2005-12-21 2009-10-01 Meda Pharma Gmbh & Co Kg Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
EP2170317A4 (en) 2007-02-12 2011-03-23 Mike Nicolaou TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2175856A4 (en) 2007-08-15 2011-08-24 Chemagis Ltd NOVEL PROCESS FOR THE PREPARATION OF HIGH-PURITY LEVOCETRIXIN AND ITS SALTS
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MX2010004563A (es) 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.
CA2701723A1 (en) 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
PT2403845E (pt) 2009-03-02 2014-08-04 Generics Uk Ltd Processo melhorado
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP2528603A4 (en) 2010-01-28 2013-09-04 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN AND OTHER DISPLAYS
US9044479B2 (en) 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
EP2598143A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
JP5996553B2 (ja) 2010-12-30 2016-09-21 ジブ エム．ディー． ハリシュ， 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物
MX2013011888A (es) 2011-04-13 2014-02-27 Revalesio Corp Composiciones y metodos para inhibir y/o modular las celulas-t efectoras involucradas en la enfermedad neurodegenerativa inflamatoria.
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
JP5860960B2 (ja) 2011-07-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キノリン類及び医薬としてのそれらの使用
CN102895661A (zh) 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
US20150322049A1 (en) 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
AU2014249530B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2017210417A1 (en) 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions

Also Published As

Publication number Publication date
ES2705244T3 (es) 2019-03-22
US20190298714A1 (en) 2019-10-03
US20150231133A1 (en) 2015-08-20
AU2011268342A1 (en) 2013-01-31
CN103002896A (zh) 2013-03-27
KR101801864B1 (ko) 2017-11-27
AU2011268342B2 (en) 2014-12-04
JP5781606B2 (ja) 2015-09-24
MX2012014521A (es) 2013-05-20
US10537568B2 (en) 2020-01-21
CA2802853C (en) 2016-07-26
US9044479B2 (en) 2015-06-02
US20130085124A1 (en) 2013-04-04
WO2011159821A1 (en) 2011-12-22
JP2015180701A (ja) 2015-10-15
EP2582373A1 (en) 2013-04-24
EP2799071B1 (en) 2018-10-17
HK1199815A1 (en) 2015-07-24
KR20130050952A (ko) 2013-05-16
KR20150038736A (ko) 2015-04-08
EP2799071A1 (en) 2014-11-05
JP2013528654A (ja) 2013-07-11
US20200323843A1 (en) 2020-10-15
EP2582373A4 (en) 2013-10-30
US20160175301A1 (en) 2016-06-23
CA2802853A1 (en) 2011-12-22
CN107308161A (zh) 2017-11-03

Similar Documents

Publication Publication Date Title
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX369385B (es) Productos para cicatrizar heridas tisulares.
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
WO2015066647A3 (en) Ionic liquids for transdermal drug delivery
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2015005798A (es) Terapia de combinacion.
EP4124346A3 (en) Compositions and methods for treating diseases
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
WO2014153385A3 (en) Methods of treating metabolic disorders
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
HK1219896A1 (zh) 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2014006662A (es) Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders